Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Product

Durvalumab

Aliases
Background Gemcitabine-based Chemotherapy Regimen, durvalumab, Durvalumab 50 MG/ML, Durvalumab (Imfinzi) immunotherapy (16 other aliases)
Name
durvalumab
Target
PDL-1
FDA Approved
No
Ema approved
Status
0

172 clinical trials

1 drug

12 abstracts

180 indications

Indication
Multiple Myeloma
Indication
Hepatocellular Carcinoma
Indication
Solid Tumors
Indication
Cervical Cancer
Indication
Advanced Solid Tumours
Indication
cancer
Indication
Non-Small Cell Lung
Indication
Small Cell Lung Cancer
Indication
Lung and Urothelial Cancers
Indication
Clear Cell Renal Cell Cancer
Indication
Lung Cancer
Indication
Breast Neoplasms
Indication
Squamous Cell Carcinoma of Head and Neck
Indication
Gastroesophageal Cancer
Indication
Melanoma
Indication
Unresectable Locally Advanced Urothelial Cancer
Indication
Metastatic Urothelial Cancer
Indication
Advanced Solid Tumor
Indication
Extensive-stage Small Cell Lung Cancer
Indication
Solid Tumours
Indication
Biliary Tract Neoplasms
Indication
Small Cell Lung Carcinoma
Indication
Ovarian Cancer
Indication
Breast Cancer
Indication
lung cancer
Indication
Stage III Non-small Cell Lung Cancer
Indication
Unresectable
Indication
Esophageal squamous cell carcinoma
Indication
Non-muscle-invasive Bladder Cancer
Indication
Non Small Cell Lung Cancer
Indication
Endometrial Neoplasms
Indication
Extensive-Stage Small-Cell Lung Cancer
Indication
Bile Duct Cancer
Indication
Solid Tumor
Indication
Muscle Invasive Bladder Cancer
Indication
Bladder Cancer
Indication
Gastrointestinal Neoplasms
Indication
Esophagogastric junction
Indication
NSCLC
Indication
Stomach Cancer
Indication
Cancer
Indication
Dose Escalation: Relapsed/Refractory Solid Tumor Malignancies or Lymphoma
Indication
Triple Negative Breast Cancer
Indication
HNSCC
Indication
Non-Hodgkin lymphoma
Indication
Non-Small Cell Lung Cancer Lymphoma
Indication
Cholangiocarcinoma
Indication
Gallbladder Cancer
Indication
Extrahepatic Cholangiocarcinoma
Indication
Gallbladder carcinoma
Indication
Hepatitis B
Indication
Chronic
Indication
lymphoma
Indication
Non-Hodgkin
Indication
Large B-Cell
Indication
Diffuse
Indication
Follicular
Indication
HER2 gene mutation
Indication
Myelodysplastic Syndromes
Indication
Prostate Cancer
Indication
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Indication
Metastatic Tumor
Indication
Locally Advanced Malignant Neoplasm
Indication
Malignant Neoplasm
Indication
Leukemia
Indication
myeloid
Indication
Acute
Indication
Pancreatic Cancer
Indication
Chondrosarcoma
Indication
Glioma
Indication
Colorectal Cancer
Indication
Progressive Metastatic Castrate-Resistant Prostate Cancer
Indication
Lymphocytic
Indication
B-cell
Indication
Non-small Cell Lung Cancer Stage III
Indication
Triple-Negative Breast Cancer
Indication
Triple-negative Breast Carcinoma
Indication
Sarcoma
Indication
Inflammatory Breast Cancer Stage III
Indication
Breast Cancer (HER2-positive)
Indication
HER2 Low Breast Adenocarcinoma
Indication
Breast Cancer, Stage IV
Indication
Triple-Negative Breast Carcinoma
Indication
Gastrointestinal Neuroendocrine Carcinoma
Indication
Colorectal cancer
Indication
Colorectal Adenocarcinoma
Indication
Refractory Cancer
Indication
Head and Neck Squamous Cell Carcinoma
Indication
Non-Small Cell Lung Cancer Stage IV
Indication
Non-Small Cell Lung Cancer Stage IIIB
Indication
Extensive-stage Small-cell Lung Cancer
Indication
Durvalumab
Indication
Lung Non-Small Cell Carcinoma
Indication
Esophageal Cancer
Indication
Merkel Cell Carcinoma
Indication
Renal Cell Carcinoma
Indication
Clinical Stage III Cutaneous Melanoma AJCC v8
Indication
Stage IV Cutaneous Melanoma
Indication
Merkel Cell Carcinoma AJCC v8
Indication
Cutaneous Melanoma
Indication
Pathologic Stage IIIB Cutaneous Melanoma AJCC v8
Indication
Stage IIIC Cutaneous Melanoma AJCC v8
Indication
Stage IIID Cutaneous Melanoma AJCC v8
Indication
Merkel Cell Carcinoma, Pathologic Stage IV, AJCC v8
Indication
Bladder Cancer Stage III AJCC v8
Indication
Stage III Lung Cancer AJCC v8
Indication
Stage III Renal Cell Cancer AJCC v8
Indication
Stage IIIA Lung Cancer
Indication
Bladder Cancer AJCC v8
Indication
Stage IIIB Lung Cancer
Indication
Stage IV Bladder Cancer
Indication
Stage IV Lung Cancer
Indication
Stage IV Renal Cell Cancer AJCC v8
Indication
Bladder Cancer, Stage IVA (AJCC v8)
Indication
Lung Cancer Stage IVA AJCC v8
Indication
Metastatic or Locally Advanced NSCLC
Indication
Stage III Non-small-cell Lung Cancer
Indication
Castration-Resistant Prostate Carcinoma
Indication
Bone Metastasis
Indication
Lung Cancer Stage III
Indication
Immunotherapy
Indication
Esophageal Adenocarcinoma
Indication
Central Nervous System Tumors
Indication
Recurrent head and neck cancer
Indication
Head and Neck Cancer
Indication
Head and Neck Neoplasms
Indication
Metastatic Cancer
Indication
Platinum-Resistant Fallopian Tube Carcinoma
Indication
Platinum-Resistant Ovarian Carcinoma
Indication
Platinum-Resistant Primary Peritoneal Carcinoma
Indication
Recurrent Fallopian Tube Carcinoma
Indication
Recurrent Ovarian Carcinoma
Indication
Recurrent Primary Peritoneal Carcinoma
Indication
Fallopian Tube Carcinoma
Indication
Primary Peritoneal Carcinoma
Indication
Locally Advanced Malignant Solid Neoplasm
Indication
Metastatic Malignant Solid Neoplasm
Indication
Metastatic Urothelial Carcinoma
Indication
Stage III Pancreatic Cancer
Indication
Renal Cell Cancer
Indication
Stage IV Renal Cell Cancer
Indication
Endometrial Cancer
Indication
Metastatic Castration-resistant Prostate Cancer
Indication
Metastatic Lung Non-Small Cell Carcinoma
Indication
Stage IV Lung Non-Small Cell Cancer AJCC v7
Indication
Thyroid Cancer
Indication
BRCA1 Mutation
Indication
BRCA2 mutation
Indication
Biliary Tract Cancer
Indication
Non-small Cell Lung Cancer Stage I
Indication
Lung Cancer Stage I
Indication
Adenocarcinoma of the Lung
Indication
Stage I
Indication
Lung Squamous Cell Carcinoma
Indication
Unresectable Pancreatic Carcinoma
Indication
Germ Cell Tumor
Indication
Nonseminomatous Germ Cell Tumor
Indication
Testicular seminoma
Indication
Germinomatous Germ Cell Tumor
Indication
Dysgerminoma
Indication
Pineal Germ Cell Tumor
Indication
Urothelial Carcinoma
Indication
Sarcomatoid Variant
Indication
Unresectable Urothelial Carcinoma
Indication
Luminal B
Indication
Esophageal cancer
Indication
Cholangiocarcinoma Metastatic
Indication
Intrahepatic Cholangiocarcinoma
Indication
Lung Adenocarcinoma
Indication
Esophageal adenocarcinoma
Indication
Stage III
Indication
Colorectal Cancer Stage IV
Indication
NED - No Evidence of Disease
Indication
Non Small Cell Lung Carcinoma
Indication
Pulmonary Large-cell Neuroendocrine Carcinoma
Indication
Colorectal Cancer Metastatic
Drug
Durvalumab (Imfinzi)
Indication
Acute Myeloid Leukemia
Indication
Anal Cancer
Indication
Anal Squamous Cell Carcinoma
Indication
B-cell Lymphoma
Clinical trial
A Phase IB Multicenter, Open-label Study To Determine The Recommended Dose And Regimen Of Durvalumab (MEDI4736) Either As Monotherapy or In Combination With Pomalidomide (POM) With Or Without Low-Dose Dexamethasone (DEX) In Subjects With Relapsed And Refractory Multiple Myeloma (RRMM)
Status: Active (not recruiting), Estimated PCD: 2018-11-23
Clinical trial
An Open-label, Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MEDI9253, a Recombinant Newcastle Disease Virus Encoding Interleukin-12, in Combination With Durvalumab in Participants With Select Advanced/Metastatic Solid Tumors
Status: Active (not recruiting), Estimated PCD: 2024-11-26
Clinical trial
An Observational Study in Patients With Unresectable Hepatocellular Carcinoma (uHCC) Following Treatment With Atezolizumab Plus Bevacizumab (AB) or With Another Approved Immuno-oncology Immune Checkpoint Inhibitor Combination in First-line
Status: Recruiting, Estimated PCD: 2026-11-27
Clinical trial
A Phase III, Randomized, Multicenter, Double-blind, Placebo-controlled Study of Durvalumab for the Treatment of Stage II-III NSCLC Patients With Minimal Residual Disease Following Surgery and Curative Intent Therapy.
Status: Completed, Estimated PCD: 2023-05-31
Clinical trial
A Phase 1/2a, Open-label, Multicenter Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of Subcutaneous Durvalumab in Patients With Non-Small Cell and Small Cell Lung Cancer - SCope-D1
Status: Terminated, Estimated PCD: 2023-08-30
Clinical trial
A Phase III, Open-label, Randomised, Multicentre Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Without Actionable Genomic Alterations, and Whose Disease Has Progressed On or After Prior Anti-PD-(L)1 Therapy and Platinum-based Chemotherapy: LATIFY
Status: Recruiting, Estimated PCD: 2025-05-22
Clinical trial
A Phase III, Randomized, Open-Label, Controlled, Multi-Center, Global Study of First-Line Durvalumab in Combination With Standard of Care Chemotherapy and Durvalumab in Combination With Tremelimumab and Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone in Patients With Unresectable Locally Advanced or Metastatic Urothelial Cancer.
Status: Active (not recruiting), Estimated PCD: 2024-08-30
Clinical trial
A Phase I First-in-Human Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of AZD8701 Administered Intravenously as Monotherapy and in Combination With Durvaluamb (MEDI4736) in Participants With Advanced Solid Tumours.
Status: Active (not recruiting), Estimated PCD: 2025-01-31
Clinical trial
A Prospective, Multicenter, Phase-IV Clinical Trial to Assess Safety of Durvalumab in Indian Adult Patients With Locally Advanced, Unresectable Non-small Cell Lung Cancer (NSCLC)
Status: Completed, Estimated PCD: 2023-10-27
Clinical trial
A Phase III, Randomized, Multicenter, Double-blind, Placebo-controlled Study to Determine the Efficacy of Adjuvant Durvalumab in Combination With Platinum-based Chemotherapy in Completely Resected Stage II-III NSCLC (MERMAID-1)
Status: Completed, Estimated PCD: 2023-08-31
Clinical trial
A Phase IIIb Single Arm, Open-label, Multicentre Study of Durvalumab and Tremelimumab as First Line Treatment in Participants With Advanced Hepatocellular Carcinoma (SIERRA)
Status: Recruiting, Estimated PCD: 2025-06-30
Clinical trial
A Phase I Multicenter Study of Immunotherapy in Combination With Chemoradiation in Patients With Advanced Solid Tumors (CLOVER)
Status: Active (not recruiting), Estimated PCD: 2020-12-31
Clinical trial
A Phase IIIb, Single-arm, Multi-center, International Study of Durvalumab in Combination With Platinum and Etoposide for the First Line Treatment of Patients With Extensive-stage Small Cell Lung Cancer (LUMINANCE)
Status: Active (not recruiting), Estimated PCD: 2023-06-12
Clinical trial
A Phase II Study to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of AZD0171 in Combination With Durvalumab and Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumours
Status: Active (not recruiting), Estimated PCD: 2024-10-07
Clinical trial
An Open-label, Multiple-Ascending Dose, Two-Part Dose Ranging and Cohort Expansion Study of INI-4001 in Patients With Advanced Solid Tumours
Status: Not yet recruiting, Estimated PCD: 2024-08-01
Clinical trial
A Phase III Randomized, Double-Blind Placebo Controlled, Multi-Regional, International Study of Durvalumab in Combination With Gemcitabine Plus Cisplatin Versus Placebo in Combination With Gemcitabine Plus Cisplatin for Patients With First-Line Advanced Biliary Tract Cancers
Status: Active (not recruiting), Estimated PCD: 2021-08-11
Clinical trial
A Phase III Randomised, Double-Blind, Placebo-Controlled, Multicentre Study of Durvalumab in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib in Newly Diagnosed Advanced Ovarian Cancer Patients (DUO-O).
Status: Active (not recruiting), Estimated PCD: 2023-09-18
Clinical trial
A Phase 1b Multicentre, Open-label, Modular, Dose-finding and Dose-expansion Study to Explore the Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of Trastuzumab Deruxtecan (T-DXd) in Combination With Other Anti-cancer Agents in Patients With Metastatic HER2-low Breast Cancer (DESTINY-Breast08)
Status: Active (not recruiting), Estimated PCD: 2023-08-16
Clinical trial
A Multicenter, Double Blind, Randomized, Controlled Study of M7824 With Concurrent Chemoradiation Followed by M7824 Versus Concurrent Chemoradiation Plus Placebo Followed by Durvalumab in Participants With Unresectable Stage III Non-small Cell Lung Cancer
Status: Terminated, Estimated PCD: 2023-02-17
Clinical trial
Savolitinib Combine With Durvalumab in Chinese EGFR Wild-type Locally Advanced or Metastatic NSCLC Patients With MET Alteration: An Open-label, Interventional, Multiple-center, Exploratory Trial (SOUND)
Status: , Estimated PCD: 2024-10-31
Clinical trial
A Phase III, Randomized, Multicenter,Open-Label, Comparative Study to Determine the Efficacy of Durvalumab or Durvalumab and Tremelimumab in Combination With Platinum-Based Chemotherapy for the First-Line Treatment in Patients With Extensive Disease Small-Cell Lung Cancer (SCLC) (CASPIAN)
Status: Active (not recruiting), Estimated PCD: 2020-01-27
Clinical trial
A Phase 2 Open-label, Multicenter, Randomized, Multidrug Platform Study of Durvalumab (MEDI4736) Alone or in Combination With Novel Agents in Subjects With Locally Advanced, Unresectable (Stage III) Non-small Cell Lung Cancer (COAST)
Status: Completed, Estimated PCD: 2023-07-18
Clinical trial
A Phase III, Double-blind, Placebo-controlled, Multi-center International Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Stages II and III Non-small Cell Lung Cancer (AEGEAN)
Status: Active (not recruiting), Estimated PCD: 2022-11-10
Clinical trial
A Phase 1b/2 Multicentre, Open-label, Modular, Dose-finding and Dose-expansion Study to Explore the Safety, Tolerability, and Anti-tumour Activity of Trastuzumab Deruxtecan (T-DXd) in Combination With Other Anti-cancer Agents in Patients With HER2-positive Metastatic Breast Cancer (DESTINY-Breast07)
Status: Active (not recruiting), Estimated PCD: 2025-01-31
Clinical trial
A Phase III Randomized, Open-Label, Multi-Center, Global Study of Durvalumab and Bacillus Calmette-Guerin (BCG) Administered as Combination Therapy Versus BCG Alone in High-Risk, BCG Naïve Non-Muscle Invasive Bladder Cancer Patients
Status: Active (not recruiting), Estimated PCD: 2024-10-31
Clinical trial
A Phase III, Randomized, Double-Blind, Placebo Controlled, Multi-Center, International Study of Durvalumab Given Concurrently With Definitive Chemoradiation Therapy in Patients With Locally Advanced, Unresectable Esophageal Squamous Cell Carcinoma (KUNLUN)
Status: Active (not recruiting), Estimated PCD: 2025-11-28
Clinical trial
A Randomised, Open-Label, Phase 2 Study of Ceralasertib Monotherapy and Ceralasertib Plus Durvalumab in Patients With Unresectable or Advanced Melanoma and Primary or Secondary Resistance to PD-(L)1 Inhibition
Status: Active (not recruiting), Estimated PCD: 2024-04-12
Clinical trial
A Multicentre, Phase II, Single-Arm, Interventional Study of Neoadjuvant Durvalumab and Platinum-based Chemotherapy (CT), Followed by Either Surgery and Adjuvant Durvalumab or Chemoradiotherapy (CRT) and Consolidation Durvalumab, in Participants With Resectable or Borderline Resectable Stage IIB-IIIB Non-small Cell Lung Cancer (NSCLC)
Status: Recruiting, Estimated PCD: 2026-04-01
Clinical trial
A Phase III, Randomized, Multi-Center, Open-Label, Comparative Global Study to Determine the Efficacy of Durvalumab or Durvalumab and Tremelimumab in Combination With Platinum-Based Chemotherapy for First-Line Treatment in Patients With Metastatic Non Small-Cell Lung Cancer (NSCLC) (POSEIDON)
Status: Active (not recruiting), Estimated PCD: 2021-03-12
Clinical trial
A Randomised, Multicentre, Double-blind, Placebo-controlled, Phase III Study of First-line Carboplatin and Paclitaxel in Combination With Durvalumab, Followed by Maintenance Durvalumab With or Without Olaparib in Patients With Newly Diagnosed Advanced or Recurrent Endometrial Cancer (DUO-E)
Status: Active (not recruiting), Estimated PCD: 2025-03-05
Clinical trial
An Open-Label, Multi-Center, Global Study to Evaluate Long Term Safety and Efficacy in Patients Who Are Receiving or Who Previously Received Durvalumab in Other Protocols (WAVE)
Status: Active (not recruiting), Estimated PCD: 2024-09-30
Clinical trial
A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Transarterial Chemoembolization (TACE) in Combination With Either Durvalumab Monotherapy or Durvalumab Plus Bevacizumab Therapy in Patients With Locoregional Hepatocellular Carcinoma (EMERALD-1)
Status: Active (not recruiting), Estimated PCD: 2023-09-11
Clinical trial
A Phase III, Open-Label, Randomized Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Patients With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer Who Have Not Progressed After Concurrent Platinum-Based Chemoradiation
Status: Active (not recruiting), Estimated PCD: 2024-10-30
Clinical trial
A Phase 3, Open-label, Multicenter, Randomized Study of Tarlatamab in Combination With Durvalumab vs Durvalumab Alone in Subjects With Extensive-Stage Small-Cell Lung Cancer Following Platinum, Etoposide and Durvalumab
Status: Not yet recruiting, Estimated PCD: 2027-09-12
Clinical trial
A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center, International Study of Durvalumab or Durvalumab and Tremelimumab as Consolidation Treatment for Patients With Limited Stage Small Cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy (ADRIATIC)
Status: Active (not recruiting), Estimated PCD: 2024-09-05
Clinical trial
A Phase I, Multi-centre, Open-label, Dose Exploration Study to Assess the Safety and Tolerability of Ceralasertib in Combination With Durvalumab in Chinese Patients With Advanced Solid Tumours
Status: Active (not recruiting), Estimated PCD: 2023-10-20
Clinical trial
Phase II Single-Arm Study of Durvalumab and Bevacizumab Following Transarterial Radioembolization Using Yttrium-90 Glass Microspheres (TheraSphere™) in Unresectable Hepatocellular Carcinoma Amenable to Locoregional Therapy
Status: Recruiting, Estimated PCD: 2026-09-30
Clinical trial
An Open-Label, Multi-Drug, Biomarker-Directed, Multi-Centre Phase II Umbrella Study in Patients With Non-Small Cell Lung Cancer, Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy (HUDSON).
Status: Active (not recruiting), Estimated PCD: 2024-09-04
Clinical trial
A Phase IIIb, Single Arm, Open-label, Multicentre Study of Durvalumab in Combination With Chemotherapy for the First Line Treatment for Patients With Advanced Biliary Tract Cancers (TOURMALINE)
Status: Recruiting, Estimated PCD: 2025-09-17
Clinical trial
A Phase 3, Randomized, Open-Label Study to Compare Ociperlimab (BGB-A1217) Plus Tislelizumab (BGB-A317) Versus Durvalumab in Patients With Locally Advanced, Unresectable, PD-L1-Selected Non-Small Cell Lung Cancer Whose Disease Has Not Progressed After Concurrent Chemoradiotherapy
Status: Terminated, Estimated PCD: 2023-10-17
Clinical trial
A Phase IB, Open-Label, Multi-Center Study to Determine the Efficacy and Safety of Durvalumab and/or Novel Oncology Therapies, With or Without Chemotherapy, for First-Line Stage IV Non-Small Cell Lung Cancer (NSCLC) (MAGELLAN)
Status: Active (not recruiting), Estimated PCD: 2023-05-23
Clinical trial
A Phase III Randomized, Open-Label, Multicenter Study to Determine the Efficacy and Safety of Durvalumab in Combination With Tremelimumab and Enfortumab Vedotin or Durvalumab in Combination With Enfortumab Vedotin for Perioperative Treatment in Patients Ineligible for Cisplatin or Who Refuse Cisplatin Undergoing Radical Cystectomy for Muscle Invasive Bladder Cancer (VOLGA)
Status: Recruiting, Estimated PCD: 2025-07-18
Clinical trial
A Phase III, Randomised,Double-Blind,Placebo-Controlled,Study of Durvalumab as Consolidation Therapy in Patients With Locally Advanced,Unresectable NSCLC, Who Have Not Progressed Following Definitive, Platinum-Based Chemoradiation Therapy
Status: Active (not recruiting), Estimated PCD: 2024-06-21
Clinical trial
A Phase III, Randomized, Open-Label, Multi-Center, Global Study to Determine the Efficacy and Safety of Durvalumab in Combination With Gemcitabine+Cisplatin for Neoadjuvant Treatment Followed by Durvalumab Alone for Adjuvant Treatment in Patients With Muscle-Invasive Bladder Cancer.
Status: Active (not recruiting), Estimated PCD: 2025-06-30
Clinical trial
An Open-Label, Prospective, Multi-Center Clinical Trial to Evaluate the Efficacy and Safety of TheraSphere™ Followed by Durvalumab (Imfinzi®) With Tremelimumab (Imjudo®) for Hepatocellular Carcinoma (HCC)
Status: Recruiting, Estimated PCD: 2026-12-01
Clinical trial
A Phase III, Randomized, Open-Label, Controlled, Multi-Center, Global Study of First-Line MEDI4736 (Durvalumab) Monotherapy and MEDI4736 (Durvalumab) in Combination With Tremelimumab Versus Standard of Care Chemotherapy in Patients With Unresectable Stage IV Urothelial Cancer
Status: Active (not recruiting), Estimated PCD: 2020-01-27
Clinical trial
A Phase III, Randomized, Placebo-controlled, Double-blind, Multi-center, International Study of Durvalumab Given Concurrently With Platinum-based Chemoradiation Therapy in Patients With Locally Advanced, Unresectable NSCLC (Stage III) (PACIFIC2)
Status: Active (not recruiting), Estimated PCD: 2023-09-07
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Phase III Study of Neoadjuvant-Adjuvant Durvalumab and FLOT Chemotherapy Followed by Adjuvant Durvalumab in Patients With Resectable Gastric and Gastroesophageal Junction Cancer (GC/GEJC)
Status: Active (not recruiting), Estimated PCD: 2025-10-31
Clinical trial
A Phase III, Randomised, Open-label, Multicentre, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Durvalumab and Carboplatin Versus Pembrolizumab in Combination With Platinum-based Chemotherapy for the First-line Treatment of Patients With Locally Advanced or Metastatic NSCLC Without Actionable Genomic Alterations (D926NC00001; AVANZAR)
Status: Recruiting, Estimated PCD: 2027-02-22
Clinical trial
A Phase 1b/2 Multicenter, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of Trastuzumab Deruxtecan (T-DXd) Monotherapy and Combinations in Adult Participants With HER2-expressing Gastric Cancer (DESTINY-Gastric-03)
Status: Recruiting, Estimated PCD: 2026-07-30
Clinical trial
A Phase II, Open-label, Multicenter, International Study of Durvalumab Following Radiation Therapy in Patients With Stage III, Unresectable Non-Small Cell Lung Cancer Who Are Ineligible for Chemotherapy
Status: Completed, Estimated PCD: 2023-03-30
Clinical trial
A Phase 1/2 Study of Durvalumab and Monalizumab in Adult Subjects With Select Advanced Solid Tumors
Status: Active (not recruiting), Estimated PCD: 2021-10-26
Clinical trial
A Phase II Randomized, Multi-Center, Double-Blind, Global Study to Determine the Efficacy and Safety of Durvalumab Plus Olaparib Combination Therapy Compared With Durvalumab Monotherapy as Maintenance Therapy in Patients Whose Disease Has Not Progressed Following Standard of Care Platinum-Based Chemotherapy With Durvalumab in First Line Stage IV Non Small Cell Lung Cancer (ORION)
Status: Active (not recruiting), Estimated PCD: 2021-01-11
Clinical trial
A Phase 1, Open-Label, Multicenter, Dose Escalation Study of mRNA-2752, a Lipid Nanoparticle Encapsulating mRNAs Encoding Human OX40L, IL-23, and IL-36γ, for Intratumoral Injection Alone and in Combination With Immune Checkpoint Blockade
Status: Active (not recruiting), Estimated PCD: 2024-05-15
Clinical trial
A Phase 1b, Multicenter, 2-Part, Open-Label Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Immunotherapy With or Without Carboplatin in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (Tropion-Lung04)
Status: Recruiting, Estimated PCD: 2026-01-30
Clinical trial
A Phase 2a, Double-blind, Placebo-controlled, Multi-center, Randomized Study Evaluating LSTA1 When Added to Standard of Care (SoC) Versus Standard of Care Alone in Subjects With Advanced Solid Tumors (BOLSTER)
Status: Recruiting, Estimated PCD: 2025-12-01
Clinical trial
A Phase 1b Study Evaluating the Safety and Efficacy of First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer
Status: Recruiting, Estimated PCD: 2025-12-30
Clinical trial
A Phase III, Randomized, Open-Label, Sponsor-Blinded, Multicenter Study of Durvalumab in Combination With Tremelimumab ± Lenvatinib Given Concurrently With TACE Compared to TACE Alone in Patients With Locoregional Hepatocellular Carcinoma (EMERALD-3)
Status: Recruiting, Estimated PCD: 2025-12-31
Clinical trial
A Phase III, Double-blind, Placebo-controlled, Randomised, Multicentre, International Study of Durvalumab Plus Oleclumab and Durvalumab Plus Monalizumab in Patients With Locally Advanced (Stage III), Unresectable Non-small Cell Lung Cancer (NSCLC) Who Have Not Progressed Following Definitive, Platinum-Based Concurrent Chemoradiation Therapy
Status: Recruiting, Estimated PCD: 2026-05-29
Clinical trial
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi Center Study of Durvalumab Monotherapy or in Combination With Bevacizumab as Adjuvant Therapy in Patients With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation
Status: Active (not recruiting), Estimated PCD: 2026-05-29
Clinical trial
A Phase III, Open-label, Randomised Study of Neoadjuvant Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients With Previously Untreated Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer (D926QC00001; TROPION-Breast04)
Status: Recruiting, Estimated PCD: 2028-03-29
Clinical trial
An Open-label, Multi-center Phase IIIb Study of Durvalumab and Tremelimumab as First-Line Treatment in Patients With Unresectable Hepatocellular Carcinoma
Status: Recruiting, Estimated PCD: 2025-03-31
Clinical trial
A Phase 3 Study of Pembrolizumab (MK-3475) in Combination With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib vs Concurrent Chemoradiation Therapy Followed by Durvalumab in Participants With Unresectable, Locally Advanced, Stage III Non-Small Cell Lung Cancer (NSCLC)
Status: Active (not recruiting), Estimated PCD: 2026-07-06
Clinical trial
A Phase IIIb, Randomized, Multicenter, Open-label Study to Assess the Efficacy of Durvalumab Plus Tremelimumab Versus Pembrolizumab in Combination With Platinum-Based Chemotherapy for First-Line Treatment in Metastatic Non-Small Cell Lung Cancer Patients With Non-Squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS (TRITON).
Status: Recruiting, Estimated PCD: 2027-08-17
Clinical trial
A Phase 2a, Open-Label Multiple Dose Study Evaluating the Safety, Tolerability, and Pharmacodynamics of Imdusiran (AB-729) in Combination With Intermittent Dosing of Durvalumab, a PD-L1 Monoclonal Antibody, in Subjects With Chronic HBV Infection
Status: Not yet recruiting, Estimated PCD: 2027-02-01
Clinical trial
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicentre, International Study of Durvalumab Plus Domvanalimab(AB154) in Participants With Locally Advanced (Stage III), Unresectable Non-small Cell Lung Cancer Whose Disease Has Not Progressed Following Definitive Platinum-based Concurrent Chemoradiation Therapy
Status: Recruiting, Estimated PCD: 2028-06-27
Clinical trial
An Exploratory Phase 1/2 Trial To Evaluate The Safety And Efficacy Of JCAR017 Combinations In Subjects With Relapsed/Refractory B-Cell Malignancies (PLATFORM)
Status: Completed, Estimated PCD: 2023-02-15
Clinical trial
DAREONᵀᴹ-8: A Phase I, Open-label, Dose Escalation and Expansion Trial of Repeated Intravenous Infusions of BI 764532 Combined With Standard of Care (Platinium, Etoposide, and Anti-PD-L1) in Patients With Extensive-stage Small Cell Lung Carcinoma
Status: Recruiting, Estimated PCD: 2025-08-20
Clinical trial
An Open-label Randomized Trial of the Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy Alone for Advanced HER2-positive Biliary Tract Cancer
Status: Recruiting, Estimated PCD: 2028-07-01
Clinical trial
A Phase II, Open-label, Multicentre, Non-comparative, Single-arm Local Study of Ceralasertib Plus Durvalumab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Without Actionable Genomic Alterations, and Whose Disease Has Progressed On or After Prior Anti-PD-(L)1 Therapy and Platinum-based Chemotherapy
Status: Active (not recruiting), Estimated PCD: 2024-06-29
Clinical trial
A Phase 2, International, Multicenter, Randomized, Open-label, Parallel Group to Evaluate the Efficacy and Safety of Cc-486 (Oral Azacitidine) Alone in Combination With Durvalumab (MEDI4736) in Subjects With Myelodysplastic Syndromes Who Fail to Achieve an Objective Response to Treatment With Azacitidine for Injection or Decitabine
Status: Completed, Estimated PCD: 2019-06-19
Clinical trial
A Phase II, Open-label, Multicentre, Randomised Study of Neoadjuvant and Adjuvant Treatment in Patients With Resectable, Early-stage (II to IIIB) Non-small Cell Lung Cancer (NeoCOAST-2)
Status: Recruiting, Estimated PCD: 2028-12-22
Clinical trial
A Phase Ib Multicenter, Open-label Study to Evaluate the Safety and Tolerability of Trastuzumab Deruxtecan (T-DXd) and Immunotherapy Agents With and Without Chemotherapy Agents in First-line Treatment of Patients With Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) and Human Epidermal Growth Factor Receptor 2 (HER2) Overexpression (OE) (DESTINY-Lung03)
Status: Recruiting, Estimated PCD: 2025-12-23
Clinical trial
ROSY-D: Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Durvalumab and Are Judged by the Investigator to Clinically Benefit From Continued Treatment
Status: , Estimated PCD: 2025-05-08
Clinical trial
A Biomarker-directed Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Whose Disease Has Progressed on First-Line Osimertinib Therapy.
Status: Active (not recruiting), Estimated PCD: 2025-05-06
Clinical trial
A Phase III, Randomized, Placebo-controlled, Double-blind, Multi-center, International Study of Durvalumab With Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients With Unresected Stage I/II, Lymph-node Negative Non-small Cell Lung Cancer (PACIFIC-4/RTOG-3515) Osimertinib Following SBRT, a Single Arm Cohort for Patients With Unresected Stage I/II, Lymph Node Negative NSCLC Harboring a Sensitizing EGFR Mutation
Status: Recruiting, Estimated PCD: 2026-03-31
Clinical trial
An Open-label, Multi-drug, Multi-center Phase II Combination Study of AZD4635 in Patients With Prostate Cancer
Status: Completed, Estimated PCD: 2021-06-16
Clinical trial
A Phase Ib/II, Open-Label, Multicentre Study to Assess Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of AZD9150 Plus Durvalumab Alone or in Combination With Chemotherapy in Patients With Advanced, Solid Tumours and Subsequently in Patients With Non-Small-Cell Lung Cancer
Status: Active (not recruiting), Estimated PCD: 2020-01-17
Clinical trial
A Phase 3 Open-label, Randomised Study of Datopotamab Deruxtecan (DatoDXd) With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual Invasive Disease in the Breast and/or Axillary Lymph Nodes at Surgical Resection Following Neoadjuvant Systemic Therapy (TROPION-Breast03)
Status: Recruiting, Estimated PCD: 2027-09-20
Clinical trial
A Phase I-III, Multicenter Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Patients Selected According to Biomarker Status, With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer
Status: Recruiting, Estimated PCD: 2029-06-17
Clinical trial
A Phase II, Open-Label, Multi-Centre, International Safety Study of Durvalumab Following Sequential Chemotherapy and Radiation Therapy in Patients With Stage III, Unresectable Non-Small Cell Lung Cancer (PACIFIC 6)
Status: Completed, Estimated PCD: 2022-12-13
Clinical trial
A Retrospective Observational, Multi-Centre, Cohort Study to Understand Real-World Treatment Patterns and Clinical Outcomes of Adult Patients With Locally Advanced, Unresectable Non-Small Cell Lung Cancer (Stage III) in Canada
Status: Completed, Estimated PCD: 2022-08-31
Clinical trial
A Phase 1, Open-Label, Dose Escalation Trial to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Activity of SNDX-6352 Monotherapy and SNDX-6352 in Combination With Durvalumab in Patients With Unresectable, Recurrent, Locally-Advanced, or Metastatic Solid Tumors
Status: Completed, Estimated PCD: 2020-11-20
Clinical trial
A Phase 1, Open-label, Dose-escalation and Expansion Study of MEDI1191 Administered Intratumorally as Monotherapy and in Combination With Durvalumab in Subjects With Advanced Solid Tumors
Status: Completed, Estimated PCD: 2023-08-24
Clinical trial
An Early Access Program for Durvalumab and Tremelimumab as First Line Treatment for Patients With Unresectable Hepatocellular Carcinoma
Status:
Clinical trial
A Randomized, Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects With Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (>= 65 Years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)
Status: Completed, Estimated PCD: 2018-12-31
Clinical trial
CODAK: A Retrospective Observational Research Study to Describe the Characteristics and Real-world Clinical Outcomes of Patients With Locally Advanced, Unresectable Stage III Non-small Cell Lung Cancer Receiving Durvalumab in the UK.
Status: Completed, Estimated PCD: 2022-09-28
Clinical trial
A Phase 1b/2, Open-Label, Study of Tivozanib in Combination With Durvalumab in Subjects With Advanced Hepatocellular Carcinoma
Status: Terminated, Estimated PCD: 2023-04-04
Clinical trial
A Phase Ib/II Clinical Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of BC3402 in Combination With Durvalumab in Patients With Advanced Hepatocellular Carcinoma
Status: Not yet recruiting, Estimated PCD: 2024-08-01
Clinical trial
An Open Label, Multicenter Study of First-Line Durvalumab Plus Platinum-Based Chemotherapy in Chinese Patients With Extensive Stage Small-Cell Lung Cancer (Oriental)
Status: Completed, Estimated PCD: 2023-03-30
Clinical trial
A Phase 1 Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Status: Active (not recruiting), Estimated PCD: 2023-07-17
Clinical trial
A Phase 1/2 Multicenter, Open-label Study to Determine the Recommended Dose and Regimen of Durvalumab (MEDI4736) in Combination With Lenalidomide (LEN) With and Without Dexamethasone (DEX)in Subjects With Newly Diagnosed Multiple Myeloma (NDMM)
Status: Completed, Estimated PCD: 2017-12-15
Clinical trial
A Phase II Multicenter, Open-Label, Single Arm Study to Determine the Efficacy, Safety and Tolerability of AZD2811 and Durvalumab Combination as Maintenance Therapy After Induction With Platinum-Based Chemotherapy Combined With Durvalumab, for the First-Line Treatment of Patients With Extensive Stage Small-Cell Lung Cancer
Status: Active (not recruiting), Estimated PCD: 2022-06-18
Clinical trial
A Phase 1b/2 Study to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of Oleclumab (MEDI9447) With or Without Durvalumab in Combination With Chemotherapy in Subjects With Metastatic Pancreatic Ductal Adenocarcinoma
Status: Completed, Estimated PCD: 2022-07-22
Clinical trial
A Phase 2, Open-label, Multicenter Study to Evaluate the Safety and Clinical Activity of Durvalumab in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (R-CHOP) or With Lenalidomide Plus R-CHOP (R2-CHOP) in Subjects With Previously Untreated, High-Risk Diffuse Large B-Cell Lymphoma
Status: Completed, Estimated PCD: 2022-04-24
Clinical trial
A Phase 1a/1b Trial Investigating the CSF-1R Inhibitor LY3022855 in Combination With Durvalumab (MEDI4736) or Tremelimumab in Patients With Advanced Solid Tumors
Status: Completed, Estimated PCD: 2018-12-14
Clinical trial
A Phase II, Open-label, Study to Assess the Efficacy, Safety, and Tolerability of AZD4635 in Combination With Durvalumab and in Combination With Cabazitaxel and Durvalumab in Patients Who Have Progressive Metastatic Castrate-Resistant Prostate Cancer (AARDVARC)
Status: Completed, Estimated PCD: 2021-11-01
Clinical trial
An Open-label Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MEDI5395 in Combination With Durvalumab in Subjects With Select Advanced Solid Tumors.
Status: Completed, Estimated PCD: 2021-11-19
Clinical trial
A Phase Ib/II, Open-label, Multicenter Study of Novel Oncology Therapies in Combination With Chemotherapy and Bevacizumab as First-line Therapy in Metastatic Microsatellite-stable Colorectal Cancer (COLUMBIA-1)
Status: Terminated, Estimated PCD: 2022-10-10
Clinical trial
A Phase 2, Multicenter, Open-label, Study to Determine the Safety and Efficacy for the Combination of Durvalumab (DURVA) and Daratumumab (DARA) (D2) in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)
Status: Terminated, Estimated PCD: 2022-01-03
Clinical trial
A Phase IIIB, Single Arm Study, of Durvalumab in Combination With Platinum-Etoposide for Untreated Patients With Extensive-Stage Small Cell Lung Cancer Reflecting Real World Clinical Practice in Spain (CANTABRICO).
Status: Completed, Estimated PCD: 2023-06-21
Clinical trial
A Phase III, Randomized, Multi-Center, Double-Blind, Global Study to Determine the Efficacy and Safety of Durvalumab in Combination With and Following Chemoradiotherapy Compared to Chemoradiotherapy Alone for Treatment in Women With Locally Advanced Cervical Cancer
Status: Completed, Estimated PCD: 2022-01-20
Clinical trial
A Phase 1/2, Open-label, Multi-center Study to Assess the Safety and Tolerability of Durvalumab (Anti-PDL1 Antibody) as Monotherapy and in Combination Therapy in Subjects With Lymphoma or Chronic Lymphocitic Leukemia
Status: Completed, Estimated PCD: 2019-03-06
Abstract
Results of the multicenter phase II FRAIL-IMMUNE trial evaluating the efficacy and safety of durvalumab combined with weekly paclitaxel carboplatin in first-line in patients (pts) with recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) not eligible for cisplatin-based therapies.
Org: Centre Léon Bérard, Centre Paul Strauss, CH Bretagne, Centre Henri Becquerel, Clinique des Ormeaux,
Clinical trial
BRIDGE Trial: Phase II Trial of durvalumaB and chemotheRapy Induction Followed by Durvalumab and Radiotherapy in larGe volumE Stage III NSCLC
Status: Active (not recruiting), Estimated PCD: 2026-06-01
Clinical trial
Precision Immuno-Oncology for Advanced Non-small Cell Lung Cancer Patients With PD-1 ICI Resistance (PIONeeR Clinical Study)
Status: Active (not recruiting), Estimated PCD: 2024-10-01
Clinical trial
A Randomized Phase 1 Trial of Neoantigen DNA Vaccine Alone vs. Neoantigen DNA Vaccine Plus Durvalumab in Triple Negative Breast Cancer Patients Following Standard of Care Therapy
Status: Terminated, Estimated PCD: 2022-11-21
Clinical trial
A Phase II Multi-Arm Study to Test the Efficacy of Immunotherapeutic Agents in Multiple Sarcoma Subtypes
Status: Active (not recruiting), Estimated PCD: 2025-12-27
Clinical trial
NEO-adjuvant Chemo-Immunotherapy in Pancreatic Cancer
Status: Recruiting, Estimated PCD: 2024-06-01
Clinical trial
TRUDI: A Phase II Study of Neoadjuvant Trastuzumab Deruxtecan and Durvalumab for Stage III, HER2-expressing Inflammatory Breast Cancer
Status: Recruiting, Estimated PCD: 2027-12-01
Clinical trial
A Phase II, Open-Label, Study of Olaparib in Combination With Either Durvalumab (MEDI4736), Selumetinib or Capivasertib, or Ceralasertib Monotherapy in Patients With Metastatic Triple-Negative Breast Cancer
Status: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
An International, Multicentre, Open-label Randomised Phase III Trial to Evaluate the Benefit of Adding Adjuvant Durvalumab After Neoadjuvant Chemotherapy Plus Durvalumab in Patients With Stage IIB-IIIB (N2) Resectable NSCLC
Status: Not yet recruiting, Estimated PCD: 2029-10-01
Clinical trial
Sequential or Up-front Triple Treatment With Durvalumab, Tremelimumab and Bevacizumab for Non-resectable Hepatocellular Carcinoma (HCC) Patients (MONTBLANC)
Status: Recruiting, Estimated PCD: 2026-12-31
Clinical trial
A Platform Study of DNA Damage Response Inhibitors in Combination With Conventional Radiotherapy in Non Small Cell Lung Cancer
Status: Recruiting, Estimated PCD: 2025-04-01
Clinical trial
First- Line Treatment With Durvalumab Plus XELOX Chemotherapy in Patients With Advanced Gastrointestinal Neuroendocrine Carcinoma: A Prospective Single-arm Phase II Study
Status: Recruiting, Estimated PCD: 2026-11-30
Clinical trial
A Phase I/II Study of Pexa-Vec Oncolytic Virus in Combination With Immune Checkpoint Inhibition in Refractory Colorectal Cancer
Status: Completed, Estimated PCD: 2020-09-24
Clinical trial
A Phase I/II Study Evaluating the Safety and Clinical Activity of Anti-PDL1 (Durvalumab [MEDI4736]) + Anti CTLA-4 (Tremelimumab) Antibodies Administrated in Combination With Stereotactic Body Radiotherapy (SBRT) in Patients With Metastatic Squamous Cell Carcinoma of Head and Neck, Lung, Oesophageus, Cervix, Vagina,Vulva or Anus
Status: Active (not recruiting), Estimated PCD: 2024-06-01
Clinical trial
Randomized Phase 2 Clinical Trial of Nab-Paclitaxel + Durvalumab (MEDI4736) + Tremelimumab + Neoantigen Vaccine Vs. Nab-Paclitaxel + Durvalumab (MEDI4736) + Tremelimumab in Patients With Metastatic Triple Negative Breast Cancer
Status: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
First Line Durvalumab in Patients With PD-L1 Positive, Advanced NSCLC With Performance Status 2 Unsuitable for Combination Chemotherapy. A Multicenter, Single-arm Phase II Trial
Status: Active (not recruiting), Estimated PCD: 2023-01-19
Clinical trial
A First-line Multi-center, Single-arm Exploratory Study Using Low-dose Radiotherapy (LDRT) Combined With Durvalumab (MEDI4736), Etoposide, and Cisplatin/Carboplatin for Patients With Extensive-stage Small Cell Lung Cancer
Status: Active (not recruiting), Estimated PCD: 2023-02-06
Clinical trial
An Open-label, Single-Center, Phase 1b/2 Study to Evaluate the Safety of Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Malignancies After Progression on PD-1 or PD-L1 Targeted Antibodies
Status: Recruiting, Estimated PCD: 2025-06-01
Clinical trial
Single Arm Phase II, Multicenter Study of Concomitant Radiotherapy, Tremelimumab and Durvalumab (MEDI4736) for Metastatic or Locally Advanced NSCLC Patients Progressing on First-line Immunotherapy
Status: Recruiting, Estimated PCD: 2026-12-01
Clinical trial
Durvalumab Plus Tremelimumab Combination Immunotherapy With or Without Weekly Paclitaxel in Patients With Advanced Biliary Tract Carcinoma (BTC) After Failure of Platinum-based Chemotherapy: a Randomized Non-comparative Two-arm Phase II Study
Status: Active (not recruiting), Estimated PCD: 2022-07-28
Clinical trial
A Phase II Randomized Study of Durvalumab and Tremelimumab and Best Supportive Care vs Best Supportive Care Alone in Patients With Advanced Colorectal Adenocarcinoma Refractory to Standard Therapies
Status: Completed, Estimated PCD: 2018-10-18
Clinical trial
Phase II Trial of Concurrent, Split Course Chemoradiation Followed by Durvalumab (MEDI4736) in Poor Risk and/or Elderly Patients With Newly Diagnosed Stage III Non-small Cell Lung Cancer
Status: Recruiting, Estimated PCD: 2026-10-31
Clinical trial
NSGO-OV-UMB1; ENGOT-OV30 / NSGO: A Phase II Umbrella Trial in Patients With Relapsed Ovarian Cancer
Status: Completed, Estimated PCD: 2021-10-19
Clinical trial
PhAse 1/2 StuDy of Modern ImmunotherApy in BCG-Unresponsive, BCG-RelaPsing, and High-Risk BCG-Naive Non-muscle Invasive UroThelial Carcinoma of the BLADDER
Status: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
A Pilot Trial to Explore the Link Between Immunological Changes, Efficacy, Safety, and Tolerability of Durvalumab (MEDI4736) Plus Tremelimumab in Chemotherapy-Naïve Men With Metastatic Castration-Resistant Prostate Cancer (CRPC)
Status: Completed, Estimated PCD: 2021-04-13
Clinical trial
Phase II Concurrent Durvalumab (MEDI4736) and Radiotherapy Followed by Consolidative Durvalumab (MEDI4736) for Stage III Non-Small Cell Lung Cancer (NSCLC)
Status: Active (not recruiting), Estimated PCD: 2025-08-01
Clinical trial
A Phase II, Multicenter, Randomized Study of Durvalumab and Lenvatinib With or Without Chemotherapy in First-Line Treatment of Advanced Biliary Tract Cancer
Status: Recruiting, Estimated PCD: 2023-12-30
Clinical trial
Randomized Phase I/II Study of Ablative Radiotherapy +/- MEDI 4736 (Durvalumab) for Medically Inoperable Early-Stage Non-Small Cell Lung Cancer
Status: Active (not recruiting), Estimated PCD: 2024-06-01
Clinical trial
Organ Preservation With Durvalumab-based Immunotherapy in Combination With Chemoradiation as Definitive Therapy for Early Stage, cT1 and cT2N0, Esophageal Adenocarcinoma With Indication for Radical Surgery: A Prospective, Multicenter Study of the FLOT-AIO Gastric Cancer Group
Status: Recruiting, Estimated PCD: 2024-08-01
Clinical trial
A Phase I, Open-Label, Single Institution Study to Assess the Safety, Tolerability, and Pharmacokinetics of Durvalumab in Pediatric Patients With Relapsed or Refractory Solid Tumors, Lymphoma, and Central Nervous System Tumors
Status: Completed, Estimated PCD: 2022-11-30
Clinical trial
Phase II Study of a Personalized Neoantigen Vaccine in Combination With Durvalumab (MEDI4736) in Extensive Stage Small Cell Lung Cancer
Status: Recruiting, Estimated PCD: 2028-03-31
Clinical trial
An Open-label, Phase II Study of Durvalumab (MEDI4736) in Combination With Cetuximab in Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
Status: Active (not recruiting), Estimated PCD: 2024-12-01
Clinical trial
A Phase 2/3, Randomized Study to Evaluate the Dose Optimization, Safety, and Efficacy of Livmoniplimab in Combination With Budigalimab in Subjects With Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) Who Have Not Previously Received Systemic Treatment
Status: Recruiting, Estimated PCD: 2030-09-06
Clinical trial
A Phase II Study of Durvalumab (MEDI4736) With or Without Tremelimumab in Patients With Metastatic Castration Resistant Prostate Cancer
Status: Active (not recruiting), Estimated PCD: 2021-11-22
Clinical trial
Randomized Phase II Trial of Durvalumab (MEDI4736) and Tremelimumab Administered in Combination Versus Sequentially in Recurrent Platinum-Resistant Epithelial Ovarian Cancer
Status: Recruiting, Estimated PCD: 2024-12-15
Clinical trial
A Pilot Window of Opportunity Study Evaluating Durvalumab (MEDI4736) in Combination With Platinum Doublet Chemotherapy Followed by Evaluation of Durvalumab (MEDI4736) in Combination With Platinum Doublet Chemotherapy and Abequolixron (RGX-104) in Non-small Cell Lung Cancer
Status: Recruiting, Estimated PCD: 2024-12-19
Clinical trial
A Phase IB Rescue Study With Oral Decitabine (AStX727) and Durvalumab (MEDI4736) Combination Therapy in Recurrent and/or Metastatic Head and Neck Cancer Patients Who Have Progressed on Anti-PD-1, Anti-PD-L1, or Anti-CTLA-4 Monotherapy
Status: Active (not recruiting), Estimated PCD: 2025-01-01
Clinical trial
Phase II Trial of Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Selected Solid Tumor Malignancies
Status: Recruiting, Estimated PCD: 2025-07-31
Clinical trial
A Phase 2 Study of MEDI4736 (Durvalumab) and Tremelimumab Alone or in Combination With High or Low-Dose Radiation in Metastatic Colorectal and NSCLC
Status: Active (not recruiting), Estimated PCD: 2023-12-31
Clinical trial
Radioiodine (RAI) in Combination With Durvalumab (Medi4736) for RAI-avid, Recurrent/Metastatic Thyroid Cancers
Status: Active (not recruiting), Estimated PCD: 2023-02-06
Clinical trial
Neoadjuvant Olaparib and Durvalumab for Patients With BRCA-associated Triple Negative Breast Cancer
Status: Withdrawn, Estimated PCD: 2028-09-06
Clinical trial
Phase I/II Clinical Trial of Regorafenib Plus Durvalumab (MEDI4736) in Patients With Chemo Refractory Advanced Biliary Tract Cancers
Status: Recruiting, Estimated PCD: 2025-11-01
Clinical trial
A Phase II Study of Circulating Tumor DNA Directed Consolidation Durvalumab (MEDI4736) Following Induction and Concurrent Durvalumab With SABR for Stage I NSCLC. SCION: SABR and Checkpoint Inhibition Of NSCLC
Status: Recruiting, Estimated PCD: 2026-12-01
Clinical trial
A Phase 1 Study of Olaparib in Combination With Durvalumab (MEDI4736) and Concurrent Radiation Therapy Following First-Line Chemotherapy in Locally Advanced Unresectable Pancreatic Cancer
Status: Recruiting, Estimated PCD: 2025-03-31
Clinical trial
A Single-arm, Phase II Study of Durvalumab (MEDI4736) and Tremelimumab for Relapsed/Refractory Germ Cell Tumors
Status: Active (not recruiting), Estimated PCD: 2024-11-01
Clinical trial
RESOLVE : A Phase I Trial of Tremelimumab + Durvalumab(MEDI4736)+ Belinostat in ARID1A Mutated Cancers With Focus on Urothelial Carcinoma
Status: Recruiting, Estimated PCD: 2024-11-30
Clinical trial
A Phase IB/II Study of Durvalumab (MEDI4736) Combined With Dose-dense EC in a Neoadjuvant Setting for Patients With Locally Advanced Luminal B HER2(-) or Triple Negative Breast Cancers.
Status: Completed, Estimated PCD: 2022-11-21
Clinical trial
Phase I/II Study of the Anti-Programmed Death Ligand-1 Antibody Durvalumab (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Cancers
Status: Recruiting, Estimated PCD: 2024-12-30
Clinical trial
Neo-adjuvant Chemo and Immunotherapy With Durvalumab (MEDI4736) and Tremelimumab (MEDI1123) In The Pre-operAtive Treatment of Locally Advanced cholangIOcarciNoma: an Exploratory and Translational Study.
Status: Recruiting, Estimated PCD: 2024-09-01
Clinical trial
Phase 1/2 Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Oesophageal Cancer
Status: Completed, Estimated PCD: 2022-06-16
Clinical trial
A Single Arm Phase 2 Study of Y-90 SIRT in Combination With Durvalumab (MEDI 4736) and Gemcitabine/Cisplatin in Locally Advanced, Unresectable or Metastatic Intrahepatic Cholangiocarcinoma
Status: Recruiting, Estimated PCD: 2026-12-01
Clinical trial
A Multicentric Phase II Trial of Stereotactic Radiotherapy Plus Durvalumab Continuation for Patients With NSCLC Metachronous Oligometastatic Disease Under Durvalumab Consolidation Following Chemoradiation
Status: Active (not recruiting), Estimated PCD: 2025-12-01
Clinical trial
A Randomized Double Blind Phase II Trial of Restorative Microbiota Therapy (RMT) in Combination With Durvalumab (MEDI4736) and Chemotherapy in Untreated Patients With Advanced or Metastatic Adenocarcinoma Non-Small Cell Lung Cancer
Status: Recruiting, Estimated PCD: 2028-01-01
Clinical trial
Phase I/II Study Assessing Safety & Efficacy of Consolidative Hypofractionated Radiation Therapy for Boosting Residual Primary Lung Cancer With Durvalumab After Definitive Chemoradiation Therapy for Stage III Non-small Cell Lung Cancer
Status: Recruiting, Estimated PCD: 2026-03-01
Clinical trial
A Phase I Study of Durvalumab (MEDI4736) Plus Tremelimumab in Combination With Platinum-based Chemotherapy in Untreated Extensive-Stage Small Cell Lung Cancer and Performance Status 2
Status: Terminated, Estimated PCD: 2021-12-15
Clinical trial
Neoadjuvant and Adjuvant Durvalumab in Combination With Neoadjuvant Chemotherapy in Patients With Operable Urothelial Cancer. A Multicenter, Single-arm Phase II Trial
Status: Active (not recruiting), Estimated PCD: 2022-02-25
Clinical trial
A Phase II Trial to Evaluate Safety and Efficacy of Adding Durvalumab (MEDI4736) to Standard Neoadjuvant Radiochemotherapy and of Adjuvant Durvalumab +/- Tremelimumab in Locally Advanced Esophageal Adenocarcinoma and to Evaluate Biomarkers Predictive for Response to Immune Checkpoint Inhibition
Status: Active (not recruiting), Estimated PCD: 2024-06-01
Clinical trial
A Randomized, Open-label, Multi-center Phase III Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma
Status: Active (not recruiting), Estimated PCD: 2021-08-27
Clinical trial
Progression-free Survival After Minimally Invasive Surgical Microwave Ablation Plus Durvalumab (MEDI4736) and Tremelimumab for Unresectable Non-metastatic Locally Advanced Pancreatic Cancer: MIMIPAC Trial
Status: Active (not recruiting), Estimated PCD: 2023-12-31
Clinical trial
Thoracic Radiotherapy Plus Durvalumab in Elderly and/or Frail NSCLC Stage III Patients Unfit for Chemotherapy - Employing Optimized (Hypofractionated) Radiotherapy to Foster Durvalumab Efficacy
Status: Recruiting, Estimated PCD: 2025-10-31
Clinical trial
Study of Adjuvant Durvalumab (MEDI4736) Plus Regorafenib vs Untreated Control in Stage IV Colorectal Cancer Patients With no Evidence of Disease (NED): VIVA Trial
Status: Recruiting, Estimated PCD: 2024-03-02
Clinical trial
A Phase III Randomized, Open-Label, Multi-Center Study of Durvalumab (MEDI4736) Versus Standard of Care (SoC) Platinum-Based Chemotherapy as First Line Treatment in Patients With PD-L1-High Expression Advanced Non Small-Cell Lung Cancer
Status: Active (not recruiting), Estimated PCD: 2022-10-27
Clinical trial
A Multicenter Phase II, Single Arm Study of Durvalumab (MEDI 4736) With Carboplatin Plus Etoposide for 4 Cycles Followed by Durvalumab Maintenance in Patients With Metastatic Pulmonary Large-cell Neuroendocrine Carcinoma (LCNEC)
Status: Recruiting, Estimated PCD: 2026-12-31
Clinical trial
A Phase 1b Trial of Adaptive Stereotactic Body Radiotherapy in Combination With Durvalumab (MEDI4736), Platinum, and Etoposide in Extensive Stage Small Cell Lung Cancer
Status: Recruiting, Estimated PCD: 2025-02-01
Clinical trial
A Phase II Trial of Pazopanib and Durvalumab for Metastatic Soft Tissue Sarcoma
Status: Completed, Estimated PCD: 2022-08-10
Clinical trial
Optical PD-L1 Imaging Using Quantitative Fluorescence Endoscopy in Locally Advanced Esophageal Cancer Using Durvalumab-680LT: a Multicenter Feasibility and Safety Study
Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
Phase Ib/II Trial Evaluating the Safety, Tolerability and Immunological Activity of Durvalumab (MEDI4736) (Anti-PD-L1) Plus Tremelimumab (Anti-CTLA-4) Combined With FOLFOX in Patients With Metastatic Colorectal Cancer
Status: Completed, Estimated PCD: 2023-01-09
Clinical trial
Durvalumab(MEDI4736)/Tremelimumab Plus Paclitaxel in Patients With Metastatic Gastric Cancer After Failure of First-line Chemotherapy, Phase Ib/II
Status: Completed, Estimated PCD: 2023-08-30
Abstract
https://www.abstractsonline.com/pp8/#!/10828/presentation/10496
Abstract
https://www.abstractsonline.com/pp8/#!/10828/presentation/10246
Abstract
https://www.abstractsonline.com/pp8/#!/10517/presentation/20253
Abstract
https://www.abstractsonline.com/pp8/#!/10517/presentation/20181
Abstract
https://www.abstractsonline.com/pp8/#!/10828/presentation/10495
Abstract
https://www.abstractsonline.com/pp8/#!/10828/presentation/10432
Abstract
https://www.abstractsonline.com/pp8/#!/10517/presentation/20184
Abstract
https://www.abstractsonline.com/pp8/#!/10517/presentation/20273
Abstract
https://www.abstractsonline.com/pp8/#!/10828/presentation/10488
Abstract
https://www.abstractsonline.com/pp8/#!/10517/presentation/21508
Abstract
CT059 / 17 - StrataPATHTM: a multicohort, non-randomized, open-label phase 2 trial to explore efficacy and safety of FDA-approved cancer therapies in novel biomarker-guided patient population
Clinical trial
Radiotherapy Dose Escalation Using Intensity-modulated Proton Therapy for Non-small-cell Lung Cancer Patients
Status: Not yet recruiting, Estimated PCD: 2026-01-01
Clinical trial
A Single-arm, Single-center Study of Durvalumab Combined With S-1 as Adjuvant Therapy for Resectable Biliary Tract Cancer(BTC) With High Risk of Recurrence
Status: Active (not recruiting), Estimated PCD: 2026-12-30